Browsing Tag
Beam Therapeutics
4 posts
One-time gene correction therapy BEAM-302 reaches pivotal AATD testing
BEAM-302 enters pivotal AATD testing as Beam Therapeutics targets accelerated approval with $1.2 billion in cash and new data due in September.
What makes gene-editing tools like CRISPR 3.0 the next frontier in precision medicine?
Delve into the next generation of gene-editing tools, such as prime editing, and see how they may revolutionize precision medicine – read more now!
Base editing 101: Is precision gene editing safer than CRISPR‑Cas9 for therapeutic use?
Is base editing safer than CRISPR? See how Beam, Verve, and Prime are using non-cutting gene editing to raise the bar for precision and clinical safety.
Base editing vs CRISPR: Why Beam Therapeutics’ sickle cell therapy may quietly become a blockbuster
Weeks after Beam’s BEAM-101 earned RMAT status, here’s why base editing may still reshape sickle cell therapy—and what investors should watch next.